Oxford, UK. 01 March 2011: PharmaVentures Ltd acted as exclusive advisor and broker to the global biopharma company, UCB in its successful strategic partnership with UK-based developer and manufacturer Aesica Pharmaceuticals.
PharmaVentures assisted, UCB in the divestment of three European manufacturing sites in Germany and Italy to Aesica Pharmaceuticals. The deal, which included a long term partnering relationship between the two parties, was finalized on 28 February 2011
The agreement ensures that Aesica will continue to manufacture formulated products for UCB over a number of years. Additionally, around 600 employees in the three sites at Monheim, Zwickau and Pianezze will continue their activity and be transferred to Aesica. For more details please go to www.aesica-pharma.co.uk/news/aesica-completes-european-acquisitions
Fintan Walton, Chief Executive of PharmaVentures, said “We were delighted to be exclusively chosen and trusted by UCB to divest three of their manufacturing businesses. To announce today yet another successful outcome for a major pharmaceutical company like UCB underscores the growing capability of PharmaVentures to the needs of the pharmaceutical industry.”
PharmaVentures is a leading life sciences transaction advisory firm with strong capabilities in finding and evaluating opportunities and negotiating deals. The transaction team has an established track record in generating outstanding value for PharmaVentures’ clients and has assisted in over 100 transactions in the past 18 years. Beyond that, PharmaVentures’ senior advisors assisted over 500 leading companies in their growth needs including the areas of partnering and M&A.
For further information:
Fintan Walton
CEO
PharmaVentures Ltd
Tel: +44 (0)1865 332733
E-mail: fintan.walton@pharmaventures.com
Website: www.pharmaventures.com
– ends –